Sanofi closes deal on Acambis

Sanofi-Aventis closes on its deal to buy Acambis today, but it's working hard to avoid losing the entrepreneurial spirit that attracted the French pharma company to the vaccine developer in the first place.

Wayne Pisano, who runs Sanofi's vaccine arm, says that Acambis would be kept at arm's length with a minimum of bureaucratic controls to slow it down. But Pisano also conceded that fostering a small-company development mentality in a big pharma subsidiary would prove to be a challenge.

But Sanofi definitely plans to grow Acambis. Pisano plans to finance new acquisitions as well as new development work for a general flu vaccines, Japanese encephalitis, West Nile and dengue fever.

- check out the report from the Financial Times

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.